142 related articles for article (PubMed ID: 9755295)
1. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
[TBL] [Abstract][Full Text] [Related]
3. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Kim MK; Nightingale C; Nicolau D
Clin Pharmacokinet; 2003; 42(11):985-96. PubMed ID: 12908854
[TBL] [Abstract][Full Text] [Related]
4. Penetration of ciprofloxacin and fleroxacin into biliary tract.
Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
[TBL] [Abstract][Full Text] [Related]
5. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
Hoogkamer JF; Kleinbloesem CH
Drugs; 1995; 49 Suppl 2():346-8. PubMed ID: 8549357
[No Abstract] [Full Text] [Related]
6. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
8. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
[TBL] [Abstract][Full Text] [Related]
9. Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
Hummler H; Richter WF; Hendrickx AG
Toxicol Appl Pharmacol; 1993 Sep; 122(1):34-45. PubMed ID: 8397453
[TBL] [Abstract][Full Text] [Related]
10. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
11. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
12. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
[TBL] [Abstract][Full Text] [Related]
13. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
Lubowski TJ; Nightingale C; Sweeney K; Quintiliani R; Zhi J
Antimicrob Agents Chemother; 1992 Mar; 36(3):651-5. PubMed ID: 1622179
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
15. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
Rubinstein E; Dautrey S; Farinoti R; St Julien L; Ramon J; Carbon C
Antimicrob Agents Chemother; 1995 Jan; 39(1):99-102. PubMed ID: 7695338
[TBL] [Abstract][Full Text] [Related]
16. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
17. The disposition kinetics, urinary excretion and dosage regimen of ciprofloxacin in buffalo calves (Bubalus bubalis).
Saini SP; Srivastava AK
Vet Res Commun; 2001 Dec; 25(8):641-9. PubMed ID: 11767010
[TBL] [Abstract][Full Text] [Related]
18. Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.
Heizmann P; Dell D; Eggers H; Gora R
J Chromatogr; 1990 Apr; 527(1):91-101. PubMed ID: 2114419
[TBL] [Abstract][Full Text] [Related]
19. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the penetration of two quinolones into intra-abdominal abscess.
Tudor RG; Youngs DJ; Yoshioka K; Burdon DW; Keighley MR
Arch Surg; 1988 Dec; 123(12):1487-90. PubMed ID: 3142444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
